Corporation
Pharmascience Inc.
- Meetings this Parliament
- 175
- With MPs
- 20
- Since Nov 2021
- 212
- Active registrations
- 1
Most recent reported meeting: Oct 13, 2026.
Lobbying by Pharmascience Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Oct 20, 2026 Receives government funding
Filed by David Goodman, Chief Executive Officer
Lobbyists
- David Goodman · Executive Chairman
- Julie Seïde · Director, Government Affairs
- Ken Gagnon · Senior Manager, Government Affairs
- Morris Goodman · Co-Founder
Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Services and Procurement Canada (PSPC), Transport Canada (TC)
What they're lobbying on (8)Hide details
- Policies aimed at reinforcing pharmaceutical supply chain.
- Discussion regarding the launch of new branded product in the rare disease space
- Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
- Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
- Policies aimed at facilitating generic drug repurposing.
- Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
- Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
- Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
Registration 725814-234102-38. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by David Goodman (205), Martin Arès (7).
-
Reported by David Goodman · In-house (corporation)
- Doug Forsyth · Directeur général, Global Affairs Canada (GAC)
- Ryan Schmelzle · Directeur adjoint, Global Affairs Canada (GAC)
- Callie Stewart · Directeur exécutif, Global Affairs Canada (GAC)
- Jean-Sébastien Nadon · Directeur adjoint, Global Affairs Canada (GAC)
and 1 moreShow fewer
- David Jean-Laniel · Directeur adjoint, Global Affairs Canada (GAC)
Policies aimed at reinforcing pharmaceutical supply chain. Read more
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
-
Reported by David Goodman · In-house (corporation)
- Celia Lourenco · Sous-ministre adjointe déléguée, Health Canada (HC)
- Greg Loyst · Directeur général, Health Canada (HC)
- Sven Schirmer · Sous-ministre adjoint, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain. Read more
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
-
Reported by David Goodman · In-house (corporation)
- Jocelyn Milburn · Directrice, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Jocelyn Milburn · Directrice, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Directeur général, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Jocelyn Milburn · Directrice, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Directeur général, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain. Read more
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
-
Reported by David Goodman · In-house (corporation)
- Patrick Halley · Sous-ministre adjoint, Finance Canada (FIN)
- Samuel Millar · Sous-ministre adjoint délégué, Finance Canada (FIN)
Policies aimed at reinforcing pharmaceutical supply chain. Read more
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
-
Reported by Martin Arès · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Policies aimed at reinforcing pharmaceutical supply chain. Read more
Policies aimed at facilitating generic drug repurposing.
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
-
Reported by Martin Arès · In-house (corporation)
- Matt Jeneroux · Member of Parliament
Economic DevelopmentHealthIndustryTaxation and Finance
-
Reported by Martin Arès · In-house (corporation)
- Samuel Saint-Vincent · Policy Advisor, Finance Canada (FIN)
Research and DevelopmentTaxation and Finance
-
Reported by Martin Arès · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustry
-
Reported by Martin Arès · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentIndustry
-
Reported by Martin Arès · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Martin Arès · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Economic DevelopmentHealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Jamee St-Hilaire · Québec Lieutenant's office, Health Canada (HC)
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Don Davies · Député
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Eric Costen · Assistant Deputy Minister, Industry, Science and Economic Development Canada, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Jamie Kippen · Chef de cabinet, Health Canada (HC)
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Ian Foucher · Chef de cabinet, Innovation, Science and Economic Development Canada (ISED)
- Bianca Hossain · Adjoint(e) principale spécial(e), Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Bianca Hossain · Sr Special Assistant, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Anthony Housefather · Member of Parliament
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Shaili Patel · Director of Policy, Health Canada (HC)
Health
-
Reported by David Goodman · In-house (corporation)
- Bianca Hossain · Sr Special Assistant, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
- Victor Kandasamy · Policy Advisor (Quebec), Health Canada (HC)
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by David Goodman · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Eric Costen · Assistant Deputy Minister, Industry, Science and Economic Development Canada, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.